Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

1.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.

PMID:
19249680
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Loges S, Mazzone M, Hohensinner P, Carmeliet P.

Cancer Cell. 2009 Mar 3;15(3):167-70. doi: 10.1016/j.ccr.2009.02.007. Review.

PMID:
19249675
[PubMed - indexed for MEDLINE]
Free Article
3.

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Ebos JM, Kerbel RS.

Nat Rev Clin Oncol. 2011 Mar 1;8(4):210-21. doi: 10.1038/nrclinonc.2011.21. Review. Erratum in: Nat Rev Clin Oncol. 2011;8(4):221. Nat Rev Clin Oncol. 2011 Jun;8(6):316.

PMID:
21364524
[PubMed - indexed for MEDLINE]
4.

Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.

Quesada AR, Medina MA, Alba E.

Bioessays. 2007 Nov;29(11):1159-68. Review.

PMID:
17935210
[PubMed - indexed for MEDLINE]
5.

Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.

Leite de Oliveira R, Hamm A, Mazzone M.

Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Review.

PMID:
21540050
[PubMed - indexed for MEDLINE]
6.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. doi: 10.1016/j.drudis.2011.01.005. Epub 2011 Jan 22. Review.

PMID:
21262381
[PubMed - indexed for MEDLINE]
7.

Antiangiogenic agents in cancer therapy.

Lenz HJ.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):17-25. Review.

PMID:
15934499
[PubMed - indexed for MEDLINE]
Free Article
8.

Angiogenesis in cancer - general pathways and their therapeutic implications.

Dimova I, Popivanov G, Djonov V.

J BUON. 2014 Jan-Mar;19(1):15-21. Review.

PMID:
24659637
[PubMed - indexed for MEDLINE]
9.

VEGF in tumor progression and targeted therapy.

Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.

Curr Cancer Drug Targets. 2013 May;13(4):423-43. Review.

PMID:
23167597
[PubMed - indexed for MEDLINE]
10.

The critical role of vascular endothelial growth factor in tumor angiogenesis.

Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH.

Curr Cancer Drug Targets. 2012 Jan;12(1):23-43. Review.

PMID:
22111836
[PubMed - indexed for MEDLINE]
11.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
[PubMed - indexed for MEDLINE]
12.

Role of angiogenesis in tumor growth and metastasis.

Folkman J.

Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8. Review.

PMID:
12516034
[PubMed - indexed for MEDLINE]
13.

Assessing the in vivo efficacy of biologic antiangiogenic therapies.

Wilson PM, LaBonte MJ, Lenz HJ.

Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Review.

PMID:
23053262
[PubMed - indexed for MEDLINE]
14.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
[PubMed - indexed for MEDLINE]
15.

Bevacizumab for advanced breast cancer.

Traina TA, Rugo HS, Dickler M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. Review.

PMID:
17512451
[PubMed - indexed for MEDLINE]
16.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
[PubMed - indexed for MEDLINE]
17.

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J.

Crit Rev Oncog. 2012;17(1):51-67. Review.

PMID:
22471664
[PubMed - indexed for MEDLINE]
18.

Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.

Gately S, Kerbel R.

Prog Exp Tumor Res. 2003;37:179-92. Review.

PMID:
12795055
[PubMed - indexed for MEDLINE]
19.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
[PubMed - indexed for MEDLINE]
20.

Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.

Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A, Presta M.

Eur Cytokine Netw. 2009 Dec;20(4):225-34. doi: 10.1684/ecn.2009.0175. Review.

PMID:
20167562
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk